Form 4: BioAffinity Technologies CEO Maria Zannes Receives Stock Grant
SEC Form 4 Filing
Maria Zannes, CEO of bioAffinity Technologies, received a grant of 8,296 shares of common stock on June 12, 2024.
Summary
- Maria Zannes, the President and CEO of bioAffinity Technologies, Inc., received 8,296 shares of common stock on June 12, 2024.
- The shares were granted as restricted stock and vested immediately.
- Following the transaction, Zannes directly owns 209,538 shares of bioAffinity Technologies, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock grant, which is a common practice.
Positives
- The grant of restricted stock to the CEO could be seen as an incentive to align her interests with those of the shareholders.
Industry Context
Stock grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock grant could potentially increase shareholder value if it incentivizes the CEO to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of transaction: Maria Zannes acquired 8,296 shares of common stock. |
| 06/14/2024 | Date of signature on the Form 4 filing. |
Keywords
stock grant, Maria Zannes, bioAffinity Technologies, BIAF, CEO, Form 4, beneficial ownership, restricted stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.